mRNA 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The mRNA Vaccine Market size is expected to reach USD 27.43 Billion in 2034 from USD 12.76 Billion (2025) growing at a CAGR of 8.88% during 2026-2034.

The global mRNA vaccine market has grown rapidly due to the successful development and deployment of messenger RNA-based vaccines. These vaccines use genetic instructions to stimulate the body's immune system to recognize and fight specific pathogens. The effectiveness of mRNA technology during global vaccination campaigns has significantly increased interest in this innovative approach to vaccine development. Pharmaceutical companies and research organizations are investing heavily in mRNA platforms to develop vaccines for a variety of infectious diseases.

Another major factor driving market growth is the flexibility and speed of mRNA vaccine development. Unlike traditional vaccine technologies, mRNA platforms can be quickly adapted to target new viruses or variants. This capability makes them highly valuable in responding to emerging health threats. Advances in delivery systems and storage technologies are also improving the stability and distribution of mRNA vaccines, supporting broader adoption worldwide.

In the future, the market is expected to expand beyond infectious disease prevention into areas such as cancer immunotherapy and personalized medicine. Ongoing research and clinical trials are exploring the potential of mRNA-based treatments for a wide range of diseases. As biotechnology innovation continues to progress, mRNA technology is likely to become a major component of next-generation medical therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

• Cancer
• Infectious Disease
• Others (Autoimmune Diseases)

By End-user

• Government Entities
• Private Hospitals & Clinics
• Others (Research Institutes, Pharmaceutical and Biotechnology Companies, etc.)

COMPANIES PROFILED

• Pfizer Inc, Moderna Inc, Novartis AG, Sanofi, Arcturus Therapeutics, Gennova Biopharmaceuticals Ltd, Aimei Vaccine Co Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Application
• 4.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Infectious Disease Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Others (Autoimmune Diseases) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast End-user
• 5.2. Government Entities Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Private Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Others (Research Institutes, Pharmaceutical and Biotechnology Companies, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 6.2.1 By Application
  • 6.2.2 By End-user
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 6.3.1 By Application
  • 6.3.2 By End-user
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 6.4.1 By Application
  • 6.4.2 By End-user
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 6.5.1 By Application
  • 6.5.2 By End-user
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 6.6.1 By Application
  • 6.6.2 By End-user
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL MRNA VACCINE INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Pfizer Inc
  • 8.2.2 Moderna Inc
  • 8.2.3 Novartis AG
  • 8.2.4 Sanofi
  • 8.2.5 Arcturus Therapeutics
  • 8.2.6 Gennova Biopharmaceuticals Ltd
  • 8.2.7 Aimei Vaccine Co. Ltd